Yakup Ergün: The effects of 960 mg sotorasib
Tejas Patil, Thoracic oncologist CU Cancer Center, shared a post by Yakup Ergün, Medical Oncologist at Antalya City Hospital, on X:
”Sobering sotorasib stats here.
- 36.5 vs 32.7% SAE rates at 960mg or 240mg dose!
- 39.4% dose reduction at 240mg dose!
This screams of a drug tox issue, and not a dose titration issue. Will need to watch combo KRAS drugs for AE profile.”
Quoting Yakup Ergün‘s post:
“Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated aNSCLC
The article persistently emphasizes the positive aspects of the 960 mg dosage. Defining a positive benefit-risk profile for a high dose, which has survival curves as below and more toxicity, does not seem realistic to me.
It is also important to remember that the monthly cost of the 960 mg dosage is ~$20,000.”
‘Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC‘ published in European Journal of Cancer
Source: Tejas Patil/X and Yakup Ergün/X